Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

encorafenib

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
BACKGROUND Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall… Expand
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2019
2019
PURPOSE To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E–mutant… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2018
Highly Cited
2018
BACKGROUND Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in… Expand
Is this relevant?
Review
2018
Review
2018
Encorafenib (Braftovi™), a BRAF inhibitor, and binimetinib (Mektovi®), a MEK inhibitor, are two orally bioavailable drugs… Expand
Is this relevant?
Highly Cited
2017
Highly Cited
2017
Preclinical evidence suggests that concomitant BRAF and EGFR inhibition leads to sustained suppression of MAPK signaling and… Expand
Is this relevant?
2017
2017
Purpose: Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2016
2016
Encorafenib (LGX818) is a new-generation BRAF inhibitor that is under evaluation in clinical trials. However, the underlying… Expand
Is this relevant?
2016
2016
3544Background: BRAFm CRC carries a poor prognosis, with survival of 5–6 months after failure of first-line therapy. Reactivation… Expand
  • figure 6
Is this relevant?
Highly Cited
2015
Highly Cited
2015
9007 Background: MEKi addition to BRAFi therapy has been reported to increase response rate (RR) and duration of response. The… Expand
Is this relevant?
2014
2014
3514 Background: In contrast to BRAFV600 mutated (BRAFm) advanced melanoma, BRAFm colorectal carcinoma (CRC) does not respond to… Expand
Is this relevant?